<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02876211</url>
  </required_header>
  <id_info>
    <org_study_id>PIERAID-2013</org_study_id>
    <nct_id>NCT02876211</nct_id>
  </id_info>
  <brief_title>Paricalcitol Improves Anemia of Inflammation</brief_title>
  <acronym>PIERAID</acronym>
  <official_title>Benefits of the Paricalcitol (Selective Vitamin D Receptor Activator) on Anemia of Inflammation in Dialysis Patients Under Erythropoiesis-stimulating Agents Treatment.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Son Espases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Son Espases</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Anemia of inflammation (AI) is a common comorbidity in hemodialysis patients. Paricalcitol is
      a selective vitamin D receptor activator with potential benefits on anti-inflammatory
      cytokines expression. The paricalcitol for the secondary hyperparathyroidism control may
      improve AI decreasing erythropoietin stimulating agents (ESAs) dosage.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Anemia of inflammation and secondary hyperparathyroidism (SHPT) are two common clinical
      complications in patients with chronic kidney disease. Eryptosis (accelerated red blood cell
      death) is a novel mechanism associated with renal anemia and several factors such us iron,
      erythropoietin and klotho (anti-aging hormone) deficiency have been associated with this
      process.

      The use of the paricalcitol may inhibit pro-inflammatory cytokines expression, especially
      interleukine-6, which is one of the most important cytokine associated with the pathogenesis
      of the AI. If the use of the paricalcitol for the SHPT control may exert direct influence on
      the erythropoiesis process is not known.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">February 2018</completion_date>
  <primary_completion_date type="Actual">February 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in ESA dosage</measure>
    <time_frame>6 months</time_frame>
    <description>Percentage of ESA doses after 6 months of the paricalcitol or placebo administration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes on ferrokinetics.</measure>
    <time_frame>6 months</time_frame>
    <description>Changes on serum iron, transferrin, ferritin, transferrin saturation and red cell distribution width at month 6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes on interleukin-6 plasma levels.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes on hepcidin plasma levels.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes on erythropoietin plasma levels.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes on systolic blood pressure.</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in mmHg determined by 24 hours ambulatory blood pressure monitoring.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes on diastolic blood pressure.</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in mmHg determined by 24 hours ambulatory blood pressure monitoring.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular serious adverse events in each arm of treatment.</measure>
    <time_frame>6 months</time_frame>
    <description>Cardiac arrest, angina pectoris. Stroke.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events related to vascular access disfunction.</measure>
    <time_frame>6 month</time_frame>
    <description>Arteriovenous fistula site hemorrhage or thrombosis. Catheter disfunction.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Anemia</condition>
  <arm_group>
    <arm_group_label>paricalcitol plus epoetin beta</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paricalcitol 2 capsules /three times per week &amp; epoetin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo plus epoetin beta</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 2 capsules/three times per week &amp; epoetin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paricalcitol</intervention_name>
    <description>Paricalcitol 2 capsules/three times per week</description>
    <arm_group_label>paricalcitol plus epoetin beta</arm_group_label>
    <other_name>Selective vitamin D receptor activation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epoetin beta</intervention_name>
    <description>epoetin 1-3 times per week</description>
    <arm_group_label>paricalcitol plus epoetin beta</arm_group_label>
    <arm_group_label>placebo plus epoetin beta</arm_group_label>
    <other_name>anti-anemic drug</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 2 capsules/three times per week</description>
    <arm_group_label>placebo plus epoetin beta</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;= 18 years.

          -  Patients with CKD on hemodialysis of any etiology..

          -  Hemoglobin between 10 and 12g/dl at least 12 weeks before enrollment in the study.

          -  Hemoglobin plasma levels stabilized: Hb variation &lt;or = 1 g / dl for the two months
             prior to inclusion in the study.

          -  Patients with anemia of renal etiology.

          -  ESA treatment with stable doses for 2 months prior to baseline.Stable dose ESA
             Definition: Variation &lt;or = 3000UI/week.

          -  Iron status: Ferritin&gt; 200 ng / mL and transferrin saturation index (IST):&gt; = 30%).

          -  KT / V &gt;= 1.2 ( Daugirdas-2nd generation).

          -  Calcium concentrations between : 8.4 to 9.5 mg / dl and phosphorus: 3.5-5.5 mg / dl.

          -  Vitamin D 25OH normal &gt;= 15 ng / ml (patients with lower levels will be supplemented
             with calcifediol 16000 IU / bi-weekly for 6 weeks in selected patients).

          -  PTHi concentrations&gt; = 150 pg / mL and &lt;or = to 300 pg / ml.

          -  Patients who accept their inclusion in the study and sign informed consent.

        Exclusion Criteria:

          -  Epoetin beta dose &gt; 18,000 IU / weekly.

          -  Pregnant woman of childbearing age or gestational wishes or not to use adequate
             contraception ( the Ogino-Knaus contraceptive method is considered unsuitable).

          -  Active bleeding episode or history of transfusion the 2 months prior to baseline.

          -  Patients with non-renal causes of anemia:malignancies, folic acid or vitamin B12
             deficiency,hemoglobinopathies, hemolysis, pure red cell aplasia secondary to
             erythropoietin.

          -  Patients treated with the selective vitamin D receptor activator in the 3 months prior
             to inclusion in the study.

          -  Acute or chronic symptomatic: heart failure (IV-NYHA), infection or inflammatory
             disease, uncontrolled hypertension that requires the suspension of epoetin beta,
             thrombocytopathies, aplastic anemia.

          -  Immunosuppressive treatment with uncontrolled Hemoglobin level

          -  Allergy to paricalcitol or any of its components.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miguel Uriol, Ph.D.M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Son Espases University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Miguel Uriol, Ph.D.M.D.</last_name>
    <phone>00-34-871-205000</phone>
    <phone_ext>75212</phone_ext>
    <email>miguelg.uriol@ssib.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Son Espases University Hospital</name>
      <address>
        <city>Palma de Mallorca</city>
        <state>Islas Baleares</state>
        <zip>07120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miguel Uriol, Ph.D.M.D.</last_name>
      <phone>00-34-871205000</phone>
      <phone_ext>75212</phone_ext>
      <email>miguelg.uriol@ssib.es</email>
    </contact>
    <investigator>
      <last_name>Sheila Cabello Pelegrin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juan Rey Valeriano, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonio Corral Paez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Angel Garcia Alvarez, Pharmacist</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sonia Jimenez Mendoza, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Manuel Luque_Ramírez, Ph.D.MD.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Miguel Uriol Rivera, Ph.D.MD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Sun CC, Vaja V, Babitt JL, Lin HY. Targeting the hepcidin-ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation. Am J Hematol. 2012 Apr;87(4):392-400. doi: 10.1002/ajh.23110. Epub 2012 Jan 31. Review.</citation>
    <PMID>22290531</PMID>
  </reference>
  <reference>
    <citation>Perlstein TS, Pande R, Berliner N, Vanasse GJ. Prevalence of 25-hydroxyvitamin D deficiency in subgroups of elderly persons with anemia: association with anemia of inflammation. Blood. 2011 Mar 10;117(10):2800-6. doi: 10.1182/blood-2010-09-309708. Epub 2011 Jan 14.</citation>
    <PMID>21239700</PMID>
  </reference>
  <reference>
    <citation>Kempe DS, Ackermann TF, Fischer SS, Koka S, Boini KM, Mahmud H, Föller M, Rosenblatt KP, Kuro-O M, Lang F. Accelerated suicidal erythrocyte death in Klotho-deficient mice. Pflugers Arch. 2009 Jul;458(3):503-12. doi: 10.1007/s00424-009-0636-4. Epub 2009 Jan 28.</citation>
    <PMID>19184092</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 12, 2016</study_first_submitted>
  <study_first_submitted_qc>August 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2016</study_first_posted>
  <last_update_submitted>February 20, 2018</last_update_submitted>
  <last_update_submitted_qc>February 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Son Espases</investigator_affiliation>
    <investigator_full_name>Miguel Giovanni Uriol Rivera</investigator_full_name>
    <investigator_title>Ph.D. MD.</investigator_title>
  </responsible_party>
  <keyword>Renal disease</keyword>
  <keyword>Erythropoiesis</keyword>
  <keyword>Erythropoietin stimulating agent</keyword>
  <keyword>Iron</keyword>
  <keyword>Klotho</keyword>
  <keyword>Selective vitamin D receptor activation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Epoetin Alfa</mesh_term>
    <mesh_term>Hematinics</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

